Cargando…

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kmak, Jamie A., Agarwal, Nikita, He, Yuting, Heilmann, Andreas M., Miller, Vincent A., Ross, Jeffrey S., Pal, Sumanta Kumar, Ali, Siraj M., Kilari, Deepak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204854/ https://www.ncbi.nlm.nih.gov/pubmed/32399016 http://dx.doi.org/10.1159/000506625

Ejemplares similares

Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant
por: Parachoniak, Christine A., et al.
Publicado: (2017)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021)

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
por: Lim, Sun Min, et al.
Publicado: (2016)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation
por: Perini, G F, et al.
Publicado: (2016)

A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations
por: Rodón, Jordi, et al.
Publicado: (2022)

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation–associated metastatic renal-cell carcinoma
por: Alsidawi, Samer, et al.
Publicado: (2018)

Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1
por: Suwala, Abigail K., et al.
Publicado: (2021)

Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report
por: Yu, Zhe, et al.
Publicado: (2021)

A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome
por: Srivastava, Siddharth, et al.
Publicado: (2022)

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex
por: Raimondo, Lucia, et al.
Publicado: (2016)

Plasma cell-free DNA–based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
por: Du, Meijun, et al.
Publicado: (2020)

Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations
por: Kingston, Belinda, et al.
Publicado: (2019)

Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer
por: Huang, Jinyong, et al.
Publicado: (2022)

A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations
por: Hardan, Antonio Y., et al.
Publicado: (2021)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits
por: Mitra, Amit K, et al.
Publicado: (2009)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma
por: Pilling, Amanda, et al.
Publicado: (2021)

Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries
por: Blankenhorn, Anne-Line, et al.
Publicado: (2017)

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2020)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Inactivation of PTEN and ZFHX3 in Mammary Epithelial Cells Alters Patterns of Collective Cell Migration
por: Dayoub, Ali, et al.
Publicado: (2022)

EPEN-25. EXCEPTIONAL CLINICAL AND IMAGING RESPONSE TO TRK-INHIBITION IN A PATIENT WITH SUPRATENTORIAL EPENDYMOMA HARBORING NTRK2 GENE FUSION
por: Mangum, Ross, et al.
Publicado: (2020)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer
por: Roa, Iván, et al.
Publicado: (2015)

The Role of Oxidative Inactivation of Phosphatase PTEN and TCPTP in Fatty Liver Disease
por: Nguyen Huu, Thang, et al.
Publicado: (2023)

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
por: Colombo, Carla, et al.
Publicado: (2022)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST
por: Keng, Vincent W., et al.
Publicado: (2012)

TGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation
por: Morris, Shelli M., et al.
Publicado: (2014)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in (V600E)BRAF Harboring Melanoma Cells
por: Jin, Hui, et al.
Publicado: (2013)

PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successfully Treated with Everolimus: A Case Report
por: Assi, Hazem I., et al.
Publicado: (2021)

An exceptional vaccination policy in exceptional circumstances
por: The Lancet Infectious Diseases
Publicado: (2021)

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis
por: Hu, Xiaoyong, et al.
Publicado: (2015)

Prognostic association of plasma cell free DNA based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration resistant prostate cancer patients
por: Kohli, Manish, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0qqvsvtau78mt27gv77oi7oouh